

Liam D King

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5658001/liam-d-king-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

12
papers

127
citations

7
h-index

11
g-index

12
ext. papers

170
ext. citations

7.4
avg, IF

2.76
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 12 | Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health Region, Democratic Republic of the Congo.. <i>PLoS Neglected Tropical Diseases</i> , 2022 , 16, e0010167 | 4.8 | 1 |
| 11 | Trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prevention in patients undergoing methotrexate therapy for hematological malignancies: A review of the literature. <i>Hematological Oncology</i> , 2021 , 39, 170-175 | 1.3 | 1 |
| 10 | Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedside. <i>European Journal of Pharmacology</i> , 2021 , 893, 173831 | 5.3 | 1 |
| 9 | The COX-2 inhibitor NS398 selectively sensitizes hypoxic HeLa cells to ionising radiation by mechanisms both dependent and independent of COX-2. <i>Prostaglandins and Other Lipid Mediators</i> , 2020 , 148, 106422 | 3.7 | 2 |
| 8 | Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 311-326 | 5.9 | 11 |
| 7 | Cyclooxygenase-2 inhibitors delay relapse and reduce Prostate Specific Antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study. <i>Prostate International</i> , 2020 , 8, 34-40 | 3.4 | 7 |
| 6 | Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial. <i>Orthopaedics and Traumatology: Surgery and Research</i> , 2019 , 105, 1073-1077 | 2.9 | 11 |
| 5 | Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. <i>Nature Communications</i> , 2019 , 10, 1788 | 17.4 | 17 |
| 4 | Achieving cross-reactivity with pan-ebolavirus antibodies. <i>Current Opinion in Virology</i> , 2019 , 34, 140-148 | 7.5 | 15 |
| 3 | The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. <i>Cell Host and Microbe</i> , 2018 , 23, 101-109.e4 | 23.4 | 25 |
| 2 | Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope. <i>MBio</i> , 2018 , 9, | 7.8 | 24 |
| 1 | The structural basis for filovirus neutralization by monoclonal antibodies. <i>Current Opinion in Immunology</i> , 2018 , 53, 196-202 | 7.8 | 12 |